Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$929K Buy
3,690
+303
+9% +$65.2K 0.19% 67
2026
Q1
$737K Buy
3,387
+98
+3% +$21.7K 0.15% 73
2025
Q4
$752K Hold
3,289
0.15% 74
2025
Q3
$762K Buy
3,289
+572
+21% +$116K 0.18% 77
2025
Q2
$504K Sell
2,717
-112
-4% -$20.8K 0.14% 85
2025
Q1
$593K Buy
2,829
+1
+0% +$194 0.17% 79
2024
Q4
$503K Buy
2,828
+186
+7% +$34.2K 0.16% 87
2024
Q3
$522K Buy
+2,642
New +$493K 0.19% 66
2021
Q3
Sell
-2,407
Closed -$271K 65
2021
Q2
$271K Hold
2,407
0.22% 56
2021
Q1
$261K Hold
2,407
0.24% 55
2020
Q4
$247K Buy
+2,407
New +$231K 0.25% 56

Other funds holding ABBV

Montis Financial's ABBV Position: Q2 2026 in Review

Montis Financial increased its AbbVie (ABBV) stake by 8.9% in Q2 2026, buying an estimated $65.2K and bringing the position to 3,690 shares worth $929K. The position accounts for 0.19% of the portfolio, ranked #67.

Montis Financial first reported a position in ABBV in Q4 2020 and has held it in 11 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Montis Financial held 3,690 shares of AbbVie worth $929K as of Q2 2026.
  • Montis Financial bought 303 AbbVie shares in Q2 2026, an estimated $65.2K.
  • AbbVie made up 0.19% of Montis Financial's portfolio in Q2 2026, its #67 holding.
  • Montis Financial first reported a position in AbbVie in Q4 2020 and has held it in 11 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Montis Financial's 13F filing for Q2 2026, filed 6 Aug 2026.